- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05206305
Sensory-Evoked Cortical Gamma Oscillation
Sensory-Evoked Cortical Gamma Oscillation: Impact on Visual Processing and Cognitive Function in Patients With Alzheimer's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The central hypothesis of the study is that sustained 40Hz gamma oscillatory sensory stimulation therapy will improve cognitive function in patients with AD. The further hypothesis is that the improvement in cognitive function will result from improved connectivity and cortical network function as measured by EEG and ERP.
The hypotheses will be tested by the following:
- - Elucidate the immediate impact of gamma oscillations on sensory processing and cognitive function by assessing cognitive function and cortical network function prior to the introduction of sensory stimulation and comparing it to post-therapeutic assessments immediately following the acute administration of therapy on visual processing.
- - Explore the short and long-term therapeutic benefits of a sub-chronic (8 weeks) treatment by assessing cognitive function and cortical network connectivity immediately after the 8 week sensory stimulation therapy. If significant changes are observed between pre-therapy and post-therapy neurophysiologic data for an individual subject, neurophysiological testing will be repeated 4 weeks following the conclusion of therapy.
- - Investigate the correlation between neurophysiology and cognitive function by assessing cognitive function and neurophysiological measures of cortical network activity at multiple time points to determine if therapeutic changes in one domain reflect changes related to the other domain.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Roberto Fernandez-Romero, MD
- Phone Number: 865-305-7242
- Email: rfernandez@utmck.edu
Study Contact Backup
- Name: Kyle Dean
- Phone Number: 865-305-2273
- Email: kdean1@utmck.edu
Study Locations
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Recruiting
- University of Tennessee Medical Center
-
Contact:
- Janet H Parkey
- Phone Number: 865-305-6194
- Email: jparkey@utmck.edu
-
Contact:
- Kyle Dean
- Phone Number: 8653059000
- Email: kdean1@utmck.edu
-
Principal Investigator:
- Roberto Fernandez-Romero, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011)
- Fluent and literate in English language
- Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research
- Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results
Exclusion Criteria:
- Not fluent and literate in English
- Severe dementia
- Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities
- Cardiac pacemakers or any other implants that may not be compatible with MRI
- Cognitively impaired to the point the patient is unable to consent for themselves
- Claustrophobic to the point that medication is required
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AD Patients
Patients with Alzheimer's Disease, as verified by positive A(beta)-PET and/or CSF tau/A(beta) biomarkers, who will receive one hour daily gamma frequency sensory stimulation from the investigational device for an 8 week period.
|
Cognito Therapeutics GammaSense Stimulation device delivers sensory (auditory and visual) stimuli at a rate of 40 Hz to the wearer for one hour each day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cortical Network Functioning
Time Frame: 8 weeks
|
Cortical visual processing assessed before and after first therapy session to evaluate immediate impact of therapy device on cortical network functioning.
The same measurements will be applied again at the conclusion of 8 week therapy period to evaluate impact of the therapy device on cortical network functioning over the total study period.
|
8 weeks
|
Cognitive Status
Time Frame: 8 weeks
|
Neuropsychological tests administered before & after 8 week therapy period. Aggregate scoring: Range 1-4. 1=All scores better than normal. 2=All scores normal. 3=1-2 scores abnormal 4=3+ scores abnormal. Tests administered are:
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resting state functional magnetic resonance imaging
Time Frame: 8 weeks
|
Resting state fMRI performed before and after the 8 week therapy.
Imaging will be compared to evaluate the impact of the investigational device on resting state cerebral network function
|
8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Roberto Fernandez-Romero, MD, University of Tennessee Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALD-001-122021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on GammaSense Stimulation device
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Dementia, Alzheimer Type | Dementia Alzheimers | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Dementia, MildUnited States
-
Emory UniversityParkinson's FoundationNot yet recruitingParkinson Disease | Gait Disorders, NeurologicUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Dementia, Alzheimer Type | Memory Disorders | Memory Impairment | Alzheimer Dementia | Memory Loss | Dementia, Mild | Memory Disorders, Age RelatedUnited States
-
Emory UniversityGeorgia Institute of TechnologyCompletedAlzheimer DiseaseUnited States
-
Neurolief Ltd.Terminated
-
Neurolief Ltd.Completed
-
University of British ColumbiaUnited States Department of DefenseNot yet recruitingSpinal Cord Injuries | Autonomic DysfunctionCanada
-
EMKinetics, IncTerminated
-
Seoul National University HospitalRecruitingDysphagiaKorea, Republic of
-
Seoul National University HospitalCompleted